

**AMENDMENTS TO THE CLAIMS**

1.(original) A compound of formula (I)  
N-Ac-Sar-Gly-AA<sup>3</sup>-AA<sup>4</sup>-AA<sup>5</sup>-AA<sup>6</sup>-AA<sup>7</sup>-Arg-Pro-AA<sup>10</sup>  
(I),

or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof, wherein  
AA<sup>3</sup> is selected from the group consisting of

- (1) glutaminyl,
- (2) phenylalanyl,
- (3) valyl, and
- (4) asparaginyl;

AA<sup>4</sup> is selected from the group consisting of

- (1) D-isoleucyl,
- (2) isoleucyl,
- (3) D-leucyl, and
- (4) D-alloisoleucyl;

AA<sup>5</sup> is selected from the group consisting of

- (1) seryl,
- (2) methionyl,
- (3) allothreonyl,
- (4) threonyl, and
- (5) tyrosyl;

AA<sup>6</sup> is selected from the group consisting of

- (1) norvalyl,
- (2) seryl,
- (3) tryptophyl,
- (4) glutaminyl, and
- (5) prolyl;

AA<sup>7</sup> is selected from the group consisting of

- (1) isoleucyl,
- (2) D-isoleucyl,
- (3) lysyl(acetyl), and
- (4) prolyl; and

AA<sup>10</sup> is selected from the group consisting of

- (1) D-alanylamide,
- (2) ethylamide, and

(3) isopropylamide;  
with the proviso that one of AA<sup>4</sup> and AA<sup>7</sup> is a D-amino acid.

2. (original) A compound according to Claim 1 wherein AA<sup>4</sup> is D-Ile.

3. (original) A compound according to Claim 2 selected from the group consisting of  
N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-Phe-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-Val-D-Ile-alloThr-Nva-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Asn-D-Ile-Thr-Nva-Lys(Ac)-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Val-D-Ile-alloThr-Ser-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Gln-D-Ile-alloThr-Nva-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Val-D-Ile-alloThr-Nva-Pro-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Val-D-Ile-Met-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>, and  
N-Ac-Sar-Gly-Val-D-Ile-alloThr-Pro-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>.

4. (original) A compound according to Claim 1 wherein AA<sup>4</sup> is D-Leu.

5. (original) A compound according to Claim 4 selected from the group consisting of  
N-Ac-Sar-Gly-Asn-D-Leu-Ser-Nva-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>, and  
N-Ac-Sar-Gly-Asn-D-Leu-Thr-Ser-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>.

6. (original) A compound according to Claim 1 wherein AA<sup>4</sup> is D-alloIle.

7. (original) A compound according to Claim 6 selected from the group consisting of  
N-Ac-Sar-Gly-Val-D-alloIle-Ser-Thr-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Gln-D-alloIle-Tyr-Nva-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Gln-D-alloIle-Thr-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-Val-D-alloIle-Thr-Trp-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH(CH<sub>3</sub>)<sub>2</sub>,  
N-Ac-Sar-Gly-Val-D-alloIle-Thr-Trp-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,  
N-Ac-Sar-Gly-Val-D-alloIle-alloThr-Gln-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>, and  
N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-Pro-D-AlaNH<sub>2</sub>.

8. (currently amended) A **pharmaceutical** composition comprising a compound of Claim

1, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof, and a pharmaceutically acceptable carrier.

9. (withdrawn)

10. (currently amended) A composition ~~for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration and diabetic retinopathy~~ comprising a peptide as defined in Claim 1, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof, in combination with a pharmaceutically acceptable carrier in an amount effective to inhibit angiogenesis.

11. (withdrawn)

12. (original) A compound selected from the group consisting of

N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,

N-Ac-Sar-Gly-Phe-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,

N-Ac-Sar-Gln-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-Ile-alloThr-Nva-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Asn-D-Leu-Ser-Nva-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-(6-Me-Nicotinyl)-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-Ile-Thr-Nva-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-alloIle-Ser-Thr-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Asn-D-Ile-Thr-Nva-Lys(Ac)-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Gln-D-alloIle-Tyr-Nva-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Gln-D-alloIle-Thr-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,

N-Ac-Sar-Gly-Asn-D-Leu-Thr-Ser-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-Ile-alloThr-Ser-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Gln-D-Ile-alloThr-Nva-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-Ile-alloThr-Nva-Pro-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-Trp-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH(CH<sub>3</sub>)<sub>2</sub>,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-Trp-D-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-D-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-Ile-Met-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,

N-Ac-Sar-Gly-Val-D-Ile-alloThr-Pro-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>,

N-Ac-Sar-Gly-Val-D-alloIle-alloThr-Gln-Ile-Arg-ProNHCH<sub>2</sub>CH<sub>3</sub>, and

N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-Pro-D-AlaNH<sub>2</sub>.

**13. (New) A composition comprising a peptide as defined in Claim 1, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof, in combination with a pharmaceutically acceptable carrier in an amount effective to inhibit growth of tumor cells.**